Secarna Pharmaceuticals GmbH & Co. KG | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Headlines Articles Press releases Secarna Pharmaceuticals GmbH & Co. KG

Home
Companies
Secarna Pharmaceuticals GmbH & Co. KG

BRIEF

published on 10/31/2024 at 16:08, 20 days 18 hours ago

Secarna Pharmaceuticals Appoints New CEO Konstantin Petropoulos

CEO Appointment Biopharmaceuticals Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
PRESS RELEASE

published on 10/31/2024 at 16:03, 20 days 18 hours ago

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office
Secarna Pharmaceuticals announces Konstantin Petropoulos as new CEO, succeeding Alexander Gebauer, focusing on oligonucleotide therapeutics. Petropoulos brings extensive industry experience

Business Development CEO Appointment Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
BRIEF

published on 09/09/2024 at 14:05, 2 months 11 days ago

Secarna Pharmaceuticals to Showcase ASO Potential at Inflammasome Therapeutics Summit

Secarna Pharmaceuticals ASOs Inflammation NLRP3 Inflammasome Therapeutics Summit
PRESS RELEASE

published on 09/09/2024 at 14:00, 2 months 11 days ago

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
Secarna Pharmaceuticals presents ASO data targeting NLRP3 at Inflammasome Therapeutics Summit, showcasing potential in inflammatory disease treatment

Secarna Pharmaceuticals ASOs NLRP3 Inflammasome Summit Inflammatory Disease
BRIEF

published on 09/04/2024 at 14:05, 2 months 16 days ago

Secarna Establishes Oncology Advisory Board with Experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Scientific Advisory Board Secarna Pharmaceuticals Oncology Experts SECN-15 Neuropilin 1
PRESS RELEASE

published on 09/04/2024 at 14:00, 2 months 16 days ago

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
Secarna Pharmaceuticals GmbH & Co. KG establishes an oncology Scientific Advisory Board with leading experts Prof. Dr. Eggermont and Prof. Dr. Zippelius to guide the development of SECN-15 and the oncology pipeline

Scientific Advisory Board Oncology Therapeutics Secarna Pharmaceuticals SECN-15
BRIEF

published on 07/22/2024 at 14:05, 3 months 29 days ago

Secarna Pharmaceuticals Publishes New Data on LNA-Modified ASOs

Secarna Pharmaceuticals ASOs Immunostimulatory Potential TLR9 Nucleic Acid Therapeutics
PRESS RELEASE

published on 07/22/2024 at 14:00, 3 months 29 days ago

Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs
Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics highlighting strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs

Secarna Pharmaceuticals ASOs Immunostimulatory Potential Nucleic Acid Therapeutics LNA-modified
BRIEF

published on 05/28/2024 at 13:05, 5 months 23 days ago

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Develop Peptide-Conjugated Antisense Therapeutics

Collaboration Secarna Pharmaceuticals Orbit Discovery Antisense Therapeutics Peptide-Conjugated
PRESS RELEASE

published on 05/28/2024 at 13:00, 5 months 23 days ago

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
Secarna Pharmaceuticals and Orbit Discovery collaborate to develop peptide-conjugated targeted antisense oligonucleotide therapeutics, expanding treatment options for various diseases

Collaboration Secarna Pharmaceuticals Orbit Discovery Peptide-Conjugated Antisense Oligonucleotide Therapeutics

Accesswire

Published on 11/21/2024 at 10:03, 30 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 33 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 33 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 58 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 8 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 28 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 31 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 33 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 33 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 32 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 35 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 13 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 48 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 48 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE